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The past two decades have witnessed a substantial increase in our understanding of histamine
interaction and functions. The main factor propelling pharmacological interests in histamine research
is its pleiotropic pathophysiological actions, which have led to the development and marketing of
many successful medications for immune and gastrointestinal disorders (Tiligada and Ennis, 2020). A
large body of research evidence has recently revealed a crucial role of histamine in cancer-related
processes such as cell cycle and proliferation, apoptosis and invasion (Massari et al., 2020). Moreover,
the discovery of the latest G protein-coupled receptor of histamine, histamine H4 receptor (H4R), and
its potent immunomodulatory effect, has opened up new perspectives in cancer research (Massari
et al., 2020). Besides its distribution on immune cells, H4R was also differentially expressed in a wide
variety of cancers, cancer models, and tumor cell lines. In this regard, we read with great interest the
elegant work of Nicoud et al., which comprehensively reviewed the recent research on the
pathophysiological role of H4R in cancer (Nicoud et al., 2019). The authors summarized
the current knowledge on H4R pharmacology, clinical applications, and differential expression in
many in vitro and in vivo experimental models of cancer as well as in cancer patient cohorts.
Importantly, authors concluded that numerous preclinical data indicated with no doubt the
participation of H4R in tumor progression and signify the potential of exploiting this receptor for
cancer treatment. In this respect, we would like to briefly highlight the involvement of H4R in oral (or
mobile) tongue squamous cell carcinoma (OTSCC), which however was not covered in this review.
OTSCC is the most commonmalignancy in the oral cavity, whichmainly arises in the lateral borders
of tongue and shows a swift metastasis to the regional lymph nodes. The prognosis of OTSCC, despite
the improvement in cancer therapy, remains low (the 5-year survival rate is about 50%) without major
improvements in survival within the past decades (Chen et al., 2018). Indeed, early diagnosis and
effective treatments, with less off-target effects, are imperative to improve the survival rates of OTSCC
patients (Chen et al., 2018). Thus, there is an urgent need to identify, test, and develop new effective
therapeutic targets for OTSCC. Histamine and H4R showed differential immunoexpression in thein.org June 2020 | Volume 11 | Article 8741
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many cancer types (Massari et al., 2020). In this sense, we
demonstrated the functional expression of H4R in cultured
human oral keratinocytes (HOKs) and also the presence of H4R
in OTSCC specimens (Salem et al., 2015; Salem et al., 2017a).
However, the intensity of H4R staining in normal oral epithelium
was significantly higher than in OTSCC tissues.
Humanmast cells represent the main precursor of histamine and
constitutively express H4R, which participates in regulating
autocrine and paracrine histamine-mediated actions (Lippert et al.,
2004). Upon stimulation, mast cells produce histamine in high
“burst-released” quantities that can induce pathophysiological
effects mainly via the classical histamine receptor subtypes (H1R
and H2R). On the other hand, other cell types, such as T
lymphocytes and epithelial cells, can synthesize and release nearly
1,000-fold less amount of histamine, which mediates physiological
effects mainly through the high-affinity receptor subtypes (H3R and
H4R) (Konttinen et al., 2013). Therefore, our group has coined a new
term to differentiate between these two cell categories based on their
capacity to synthesize and produce histamine (Konttinen et al.,
2013). In this regard, cells that are able to produce and store large
(often micromolar) concentrations of histamine in secretory
granules (e.g. mast cells, basophils, and enterochromaffin-like cells)
were termed “professional histamine producing cells.” Alternatively,
cells that exhibit no capacity to store the newly formed histamine,
but they transport it passively to the extracellular milieu in a
concentration gradient manner, were termed “non-professional
histamine producing cells” (Salem et al., 2017b).
Interestingly, cultured HOKs can release low amounts of
histamine to the extracellular environment, which is able to
sensitize the high-affinity H4R in autocrine and paracrine modes
(Salem et al., 2017b). Thus, HOKs were considered as non-
professional histamine-producing cells. In OTSCC patients, the
H4R immunoreactivity was inversely correlated with the
histopathological grade of the specimen and with the numbers of
the professional histamine producing mast cells. Furthermore, the
expression of H4R at both receptor and gene levels was reduced in
two different OTSCC cell lines compared with the normal HOKs
(Salem et al., 2017a). OTSCC can arise from dysplastic and
potentially malignant lesions, such as oral lichen planus, which
also showed lower expression of H4R and increased numbers of
mast cells compared with non-dysplastic tissue (Salem et al., 2017a)
(Figure 1). More importantly, supernatants collected from culturedFrontiers in Pharmacology | www.frontiersin.org 2human mast cells showed regulatory effects on oral oncogenes in
HOKs (e.g., epidermal growth factor receptor), while high
concentration of mast cell-derived histamine downregulated H4R
gene in the same cell lines (Salem et al., 2015; Salem et al., 2017a).
The local concentrations of histamine in tumor tissue can influence
the specificity of histamine responses (Konttinen et al., 2013). In
this context and based on the implications stemming from the
aforementioned classification of cells based on their histamine
production capacity, we encourage the authors and field
researchers to consider the role of tumor-associated mast cells
when assessing H4R expression in different stages of tumorigenesis.
The role of H4R in oral tumorigenesis is not yet fully
understood. However, according to the currently available data,
H4R seems to impart antitumorigenic properties and plays a
crucial role in the maintenance of normal epithelium. Thus, H4R
agonists could offer promising therapeutic target in the treatment
of solid tumors (Martinel Lamas et al., 2013). However, we
acknowledge the limitations of our studies including a limited
sample size and lack of animal model experiments to validate the
in vitro findings, and thus further studies are warranted. In
addition, the selectivity of some H4R antibodies poses an
additional limitation in H4R-research, as there are considerable
structural similarities between H4R and H3R. Finally, we
perfectly agree with the authors that several challenges remain
to be addressed in H4R-based translational research. Such
limitations include, but are not limited to, ligand selectivity,
experimental models' heterogeneity, and the undetermined
specificity of many commercially available antibodies (Nicoud
et al., 2019). Nevertheless, the ongoing extensive investment in
H4R research indicates that exploiting this receptor in cancer
therapy could be feasible in the near future.AUTHOR CONTRIBUTIONS
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